ReviewMolecules (Basel, Switzerland)2022
Recent Applications of the Multicomponent Synthesis for Bioactive Pyrazole Derivatives.
Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 94 citations in OpenAlex.
- Multi-targeted pyrazole scaffolds: synthesis, mechanistic insights, and therapeutic potential in anticancer, antioxidant, and anti-inflammatory applications.The Libyan journal of medicine · 2026Article
- The Pschorr Reaction: Recent Advances and Application in Heterocyclic Synthesis.Molecules (Basel, Switzerland) · 2026Review
- Synthesis, docking, SAR and ADMET evaluation of novel pyrrolo[3,4-c]pyrazole-4,6-dione derivatives.Scientific reports · 2026Article
- Review
- Preparation of Hierarchically Structured Perlite NPs/Metformin-Co (II) System to Catalyze the Green Synthesis of Pyrazolopyranopyrimidines.ChemistryOpen · 2025Article
- Advancements in the design and development of pyrazoline-based antimycobacterial agents: an update and future perspectives.RSC advances · 2025Review
- Synthesis and Neurotropic Activity of New 5-Piperazinopyrazolo[3,4-Pharmaceuticals (Basel, Switzerland) · 2025Article
- Recent advances in the synthesis of anticancer pyrazole derivatives using microwave, ultrasound, and mechanochemical techniques.RSC advances · 2025Review
- Magnetically recoverable catalysts for efficient multicomponent synthesis of organosulfur compounds.RSC advances · 2025Review
- Chemoinformatics exploration of synthetically accessibleIn silico pharmacology · 2025Article
- Synthesis, characterization, biological activities, and computational studies of pyrazolyl-thiazole derivatives of thiophene.RSC advances · 2024Article
- Crystal structure, spectroscopy, DFT, and thermal studies of 3-cyano-2(1RSC advances · 2024Article
- Synthesis, DFT, andHeliyon · 2024Article
- Multicomponent Synthesis of New Fluorescent Boron Complexes Derived from 3-Hydroxy-1-phenyl-1Molecules (Basel, Switzerland) · 2024Article
- Review
- Synthesis, In Silico Study, and In Vitro Antifungal Activity of New 5-(1,3-Diphenyl-1International journal of molecular sciences · 2024Article
- Synthesis,Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Structure-Activity Relationship Studies on Highly Functionalized Pyrazole Hydrazones and Amides as Antiproliferative and Antioxidant Agents.International journal of molecular sciences · 2024Article
- Nanomagnetic CoFeNanoscale advances · 2024Article
- Discovery of Pyrano[2,3-Pharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyrazole and its derivatives are considered a privileged
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.